Amplyx Pharmaceuticals

Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening invasive fungal infections due to candida, aspergillus and rare molds. Patients undergoing chemotherapy and other immunosuppressive treatments end up with compromised immune systems. This makes them susceptible to a new disease—invasive fungal infections. Amplyx is advancing a novel small-molecule therapy, APX001, in clinical development. The Phase 1 program for APX001 is using both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenient treatment after discharge.

Amplyx Pharmaceuticals

San Diego, CA

Website

03.19.2018
Amplyx Pharmaceuticals Receives Fourth “Qualified Infectiou…

Read More

08.02.2017
Amplyx Pharmaceuticals Raises $67 Million in Series C Financing

Read More